| Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ... Clinical Cancer Research 23 (8), 1920-1928, 2017 | 1206 | 2017 |
| A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ... The Lancet Oncology 19 (9), 1180-1191, 2018 | 917 | 2018 |
| High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ... Cancer discovery 7 (6), 586-595, 2017 | 662 | 2017 |
| Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020 | 450 | 2020 |
| Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria M Tazdait, L Mezquita, J Lahmar, R Ferrara, F Bidault, S Ammari, ... European Journal of Cancer 88, 38-47, 2018 | 303 | 2018 |
| Outcome of patients with non–small cell lung cancer and brain metastases treated with checkpoint inhibitors LEL Hendriks, C Henon, E Auclin, L Mezquita, R Ferrara, ... Journal of Thoracic Oncology 14 (7), 1244-1254, 2019 | 210 | 2019 |
| Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics A Carré, G Klausner, M Edjlali, M Lerousseau, J Briend-Diop, R Sun, ... Scientific reports 10 (1), 12340, 2020 | 186 | 2020 |
| Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials C Ferté, M Fernandez, A Hollebecque, S Koscielny, A Levy, C Massard, ... Clinical Cancer Research 20 (1), 246-252, 2014 | 178 | 2014 |
| Integrating deep learning CT-scan model, biological and clinical variables to predict severity of COVID-19 patients N Lassau, S Ammari, E Chouzenoux, H Gortais, P Herent, M Devilder, ... Nature communications 12 (1), 1-11, 2021 | 159 | 2021 |
| Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules FZ Mokrane, L Lu, A Vavasseur, P Otal, JM Peron, L Luk, H Yang, ... European radiology 30, 558-570, 2020 | 144 | 2020 |
| Long-term survival in patients responding to anti–PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation ML Gauci, E Lanoy, S Champiat, C Caramella, S Ammari, S Aspeslagh, ... Clinical Cancer Research 25 (3), 946-956, 2019 | 125 | 2019 |
| Breast elastography: the technical process and its applications C Balleyguier, L Ciolovan, S Ammari, S Canale, S Sethom, ... Diagnostic and interventional imaging 94 (5), 503-513, 2013 | 124 | 2013 |
| Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort L Albiges, S Foulon, A Bayle, B Gachot, F Pommeret, C Willekens, ... Nature Cancer 1 (10), 965-975, 2020 | 123 | 2020 |
| 18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti–programmed death 1 immune checkpoint inhibitor L Dercle, RD Seban, J Lazarovici, LH Schwartz, R Houot, S Ammari, ... Journal of Nuclear Medicine 59 (1), 15-24, 2018 | 121 | 2018 |
| Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors RD Seban, L Mezquita, A Berenbaum, L Dercle, A Botticella, ... European journal of nuclear medicine and molecular imaging 47, 1147-1157, 2020 | 113 | 2020 |
| Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1 A Mekki, L Dercle, P Lichtenstein, A Marabelle, JM Michot, O Lambotte, ... European Journal of Cancer 96, 91-104, 2018 | 113 | 2018 |
| Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics RD Seban, JS Nemer, A Marabelle, R Yeh, E Deutsch, S Ammari, ... European journal of nuclear medicine and molecular imaging 46, 2298-2310, 2019 | 103 | 2019 |
| Intratumoral immunotherapy: from trial design to clinical practice S Champiat, L Tselikas, S Farhane, T Raoult, M Texier, E Lanoy, ... Clinical Cancer Research 27 (3), 665-679, 2021 | 92 | 2021 |
| Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence L Dercle, S Ammari, M Bateson, PB Durand, E Haspinger, C Massard, ... Scientific reports 7 (1), 7952, 2017 | 85 | 2017 |
| Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson L Fournier, S Ammari, R Thiam, CA Cuénod Diagnostic and interventional imaging 95 (7-8), 689-703, 2014 | 77 | 2014 |
